兵庫県立がんセンターは、兵庫県明石市にある県立病院。兵庫県の都道府県がん診療連携拠点病院、医師の卒後臨床研修指定病院でもある。

During the past decade, Hyogo Cancer Center conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 19 clinical trials were completed, i.e. on average, 54.3% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 11 clinical trials were completed. i.e. 78.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hyogo Cancer Center" #1 sponsor was "Pfizer" with 11 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Daiichi Sankyo, Inc." with 3 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hyogo Cancer Center" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Japanese Gynecologic Oncology Group" with 2 trials as a collaborator and "Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies" with 2 trials as a collaborator. Other collaborators include 26 different institutions and companies that were collaborators in the rest 35 trials.

According to Clinical.Site data, the most researched conditions in "Hyogo Cancer Center" are "Carcinoma, Non-Small-Cell Lung" (6 trials), "Ovarian Cancer" (6 trials), "Fallopian Tube Cancer" (5 trials), "Breast Cancer" (4 trials) and "Non-Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Hyogo Cancer Center" in a lesser frequency.

Most popular intervention types in "Hyogo Cancer Center" are "Drug" (48 trials), "Biological" (1 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Atezolizumab" (5 trials), "Carboplatin" (5 trials), "Docetaxel" (5 trials) and "Paclitaxel" (5 trials). Other intervention names were less common.

The vast majority of trials in "Hyogo Cancer Center" are 36 trials for "All" genders and 14 trials for "Female" genders.

Currently, there are NaN active trials in "Hyogo Cancer Center". undefined are not yet recruiting, 8 are recruiting, 17 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Hyogo Cancer Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Hyogo Cancer Center, 6 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".